The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 15 results:
Author Title [ Type(Desc)] Year
Filters: Author is Elisaf, Moses  [Clear All Filters]
Journal Article
Athyros, V. G., Liberopoulos E. N., Mikhailidis D. P., Papageorgiou A. A., Ganotakis E. S., Tziomalos K., et al. (2007).  Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort.. Angiology. 58(6), 689-97.
Chimonas, T., Karagiannis A., Athyros V. G., Achimastos A., Elisaf M., & Panagiotakos D. B. (2010).  Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis.. Metab Syndr Relat Disord. 8(6), 523-9.
Chimonas, T., Athyros V. G., Ganotakis E., Nicolaou V., Panagiotakos D. B., Mikhailidis D. P., et al. (2010).  Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome.. Angiology. 61(1), 49-57.
Katsiki, N., Tziomalos K., Chatzizisis Y., Elisaf M., & Hatzitolios A. I. (2010).  Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental?. Atherosclerosis. 211(1), 9-14.
Athyros, V. G., Mikhailidis D. P., Liberopoulos E. N., Kakafika A. I., Karagiannis A., Papageorgiou A. A., et al. (2007).  Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study.. Nephrol Dial Transplant. 22(1), 118-27.
Achimastos, A., Alexandrides T., Alexopoulos D., Athyros V., Bargiota A., Bilianou E., et al. (2016).  Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.. Hormones (Athens). 15(1), 8-14.
Athyros, V. G., Mikhailidis D. P., Kakafika A. I., Karagiannis A., Hatzitolios A., Tziomalos K., et al. (2007).  Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.. Curr Drug Targets. 8(3), 483-8.
Kotsis, V., Tsioufis K., Antza C., Seravalle G., Coca A., Sierra C., et al. (2018).  Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, ea. J Hypertens. 36(7), 1441-1455.
Kotsis, V., Jordan J., Micic D., Finer N., Leitner D. R., Toplak H., et al. (2018).  Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension. J Hypertens. 36(7), 1427-1440.
Karagiannis, A., Mikhailidis D. P., Athyros V. G., Kakafika A. I., Tziomalos K., Liberopoulos E. N., et al. (2007).  The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opin Ther Targets. 11(2), 191-205.
Athyros, V. G., Giouleme O., Ganotakis E. S., Elisaf M., Tziomalos K., Vassiliadis T., et al. (2011).  Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study.. Arch Med Sci. 7(5), 796-805.
Karagiannis, A., Athyros V. G., Papageorgiou A., Tziomalos K., & Elisaf M. (2006).  Should atenolol still be recommended as first-line therapy for primary hypertension?. Hellenic J Cardiol. 47(5), 298-307.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Pagourelias E. D., Savvatianos S. D., Elisaf M., et al. (2007).  Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients.. Open Cardiovasc Med J. 1, 8-14.
Athyros, V. G., Karagiannis A., Kakafika A., Elisaf M., & Mikhailidis D. P. (2007).  Statins and renal function. Is the compound and dose making a difference?. Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
Athyros, V. G., Mikhailidis D. P., Papageorgiou A. A., Didangelos T. P., Peletidou A., Kleta D., et al. (2005).  Targeting vascular risk in patients with metabolic syndrome but without diabetes.. Metabolism. 54(8), 1065-74.

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.